Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Andre Damons | Photo Andre Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Director of Pharmacology in the Department of Pharmacology at the UFS, hosted the first IKS Bio-Trade Indaba, which took place between 24 and 25 November on the Bloemfontein Campus of the UFS.

The inaugural international Indigenous Knowledge and Bio-Trade Indaba, hosted by the University of the Free State (UFS) in collaboration with the Technology Innovation Agency (TIA) – an entity of the Department of Science and Innovation (DSI) – is the ideal platform for various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, conservation, innovation, and commercialisation of the IK-based researched products. 

The IKS Bio-Trade Indaba was championed by the university’s African Medicines Innovation and Technology Development Platform (AMITD), which is funded by TIA. AMITD was established to stimulate economic growth by providing science-based solutions and developing technologies that would utilise indigenous knowledge and South African biodiversity to produce high-quality African traditional-medicine-based proprietary products, focusing on priority diseases. AMITD is a national leader in research, development, and formulation research on traditional medicines and has a strong history in IKS research, community collaboration, and participation initiatives, as well as partnerships with industry on herbal medicines.

The indaba, which took place from 24 to 25 November, was a success, opening much-needed dialogue and engagement on the role of IK-based knowledge in research and commercialisation. Going forward, the indaba will be a vital platform to enhance the role of IKS in inclusive development and transformation.

African traditional medicine should be internationally recognised

Prof Motlalepula Matsabisa, Director of Pharmacology in the UFS Department of Pharmacology and AMITD, said he has a special interest in the pharmacology of traditional medicines and that he wants to see more national, continental, and international collaboration so that the dream of making ATM internationally recognised and a global force can be realised. 

“How do we develop new drugs and medicines based on the knowledge we have. We do this without compromising on good all-inclusive science on ATM. We should take the science and put it on the global stage so that all people will begin to respect it,” said Prof Matsabisa. 

According to him, research conducted by AMITD should address national research priorities, community research needs and aspirations to respond to industry research questions and challenges and develop products, intellectual property (IP), as well as commercialisation. “Research needs to have a societal impact and must impact the quality of life of people. We do responsive research that needs to address old diseases, new diseases, neglected diseases, current pandemics, as well as new and re-emerging pandemics.” 

Elevation of IKS profile can no longer be delayed
 
Dr Vuyisile Phehane, Executive: Bio-Economy at the TIA, said the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. TIA acknowledges the rich, largely untapped source of knowledge within communities that has yet to be fully exploited for the economic and social benefit of particularly the underserved regions of the country, and it should be systematically well researched. 

Dr Vuysile Phehane
Dr Phehane, gave a message of support from TIA, saying the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. (Photo: Andre Damons)


“Sectoral support priorities in agriculture, manufacturing, health innovations, and allied health cannot be overlooked, and neither can the various master plans created to support industrial sectors. This thought leadership has a direct bearing on what we are doing here, engaging in dialogue to shape our future, and seeking ways to collaborate and build long-lasting partnerships in the space of IKS. These partnerships not only serve us in the country, but also on the African continent,” said Dr Phehane. 

According to him, TIA played the role of industry builder and sought to increase its efforts to grow and enhance the role of IKS in inclusive development and transformation. The successful commercialisation of all indigenous knowledge-based projects involving the use of indigenous plants requires the capacity to commercially cultivate these plants. 

Dr Phehane said TIA funded AMITD to ensure that the products of promising indigenous knowledge innovations are safe, effective, and of consistently high quality. “This platform seeks to address generations of market failure by bringing IK into the mainstream of commercialisation and truly equitable benefit sharing. Going forward, 20% of our annual MTEF allocation will be channelled towards IK initiatives, which is significant. This is testament to our commitment to IKS.”

The two-day indaba hosted various panel discussions on multiple aspects of IKS research and developments in human and plant health. Among these were discussions on cannabis research to mitigate cancer multidrug resistance, phytoconstituents for the treatment of diabetes, the development of PHELA, a plant-based product as a treatment for COVID-19, natural product-based colon regulator commercialisation, the development of cannabis and other medicinal plants in wound healing and developing hydrogels, as well as the development of IK-based herbal pesticides.

Discussions also focused on new developments in the indigenous health infusion industry, developments in medicine regulations and IK-based clinical trials in South Africa, as well as African medicines research internationalisation. International panellists included Prof Minke Tang (Beijing University of Chinese Medicine), Dr Samuel Obakiro (HOD, Department of Pharmacology, Busitema University, Uganda), and Dr Kofi Donkor (Centre for Plant Medicine Research, Mampong, Ghana), all of whom shared experiences on IKS-related research in their respective countries.

IKS one of the areas targeted for investment and growth 

Dr Glen Taylor, Senior Director: Research Development at the UFS, said the Department of Pharmacology is one of the fastest-growing departments in the Faculty of Health Sciences at the UFS, and attracts a large number of applications from national and international scholars largely due to a very understated Prof Matsabisa.

“We always look at areas where we need to invest in the future and grow, and IKS is one of those areas we targeted and invested in significantly. Through the research and work in IKS, this is done to reposition the institution as a research-led university that is relevant to its communities and societies.” 
The TIA UFS IKS International Indaba was funded by the TIA IKS unit and the Department of Pharmacology – AMITD platform.

News Archive

Stem cell research and human cloning: legal and ethical focal points
2004-07-29

   

(Summary of the inaugural lecture of Prof Hennie Oosthuizen, from the Department of Criminal and Medical Law at the Faculty of Law of the University of the Free State.)

 

In the light of stem cell research, research on embryo’s and human cloning it will be fatal for legal advisors and researchers in South Africa to ignore the benefits that new bio-medical development, through research, contain for this country.

Legal advisors across the world have various views on stem cell research and human cloning. In the USA there is no legislation that regulates stem cell research but a number of States adopted legislation that approves stem cell research. The British Parlement gave permission for research on embryonic stem cells, but determined that it must be monitored closely and the European Union is of the opinion that it will open a door for race purification and commercial exploitation of human beings.

In South Africa the Bill on National Health makes provision for therapeutical and non therapeutical research. It also makes provision for therapeutical embryonical stem cell research on fetuses, which is not older than 14 days, as well as for therapeutical cloning under certain circumstances subject to the approval of the Minister. The Bill prohibits reproductive cloning.

Research on human embrio’s is a very controversial issue, here and in the rest of the world.

Researchers believe that the use of stem cell therapy could help to side-step the rejection of newly transplanted organs and tissue and if a bank for stem cell could be built, the shortage of organs for transplants would become something of the past. Stem cells could also be used for healing of Alzheimer’s, Parkinson’s and spinal injuries.

Sources from which stem cells are obtained could also lead to further ethical issues. Stem cells are harvested from mature human cells and embryonic stem cells. Another source to be utilised is to take egg cells from the ovaries of aborted fetuses. This will be morally unacceptable for those against abortions. Linking a financial incentive to that could become more of a controversial issue because the woman’s decision to abort could be influenced. The ideal would be to rather use human fetus tissue from spontaneous abortions or extra-uterine pregnancies than induced abortions.

The potential to obtain stem cells from the blood of the umbilical cord, bone-marrow and fetus tissue and for these cells to arrange themselves is known for quite some time. Blood from the umbilical cord contains many stem cells, which is the origin of the body’s immune and blood system. It is beneficial to bank the blood of a newborn baby’s umbilical cord. Through stem cell transplants the baby or another family member’s life could be saved from future illnesses such as anemia, leukemia and metabolic storing disabilities as well as certain generic immuno disabilities.

The possibility to withdraw stem cells from human embrio’s and to grow them is more useable because it has more treatment possibilities.

With the birth of Dolly the sheep, communities strongly expressed their concern about the possibility that a new cloning technique such as the replacement of the core of a cell will be used in human reproduction. Embryonic splitting and core replacement are two well known techniques that are associated with the cloning process.

I differentiate between reproductive cloning – to create a cloned human embryo with the aim to bring about a pregnancy of a child that is identical to another individual – and therapeutically cloning – to create a cloned human embryo for research purposes and for healing human illnesses.

Worldwide people are debating whether to proceed with therapeutical cloning. There are people for and against it. The biggest ethical objection against therapeutical cloning is the termination of the development of a potential human being.

Children born from cloning will differ from each other. Factors such as the uterus environment and the environment in which the child is growing up will play a role. Cloning create unique children that will grow up to be unique individuals, just like me and you that will develop into a person, just like you and me. If we understand this scientific fact, most arguments against human cloning will disappear.

Infertility can be treated through in vitro conception. This process does not work for everyone. For some cloning is a revolutionary treatment method because it is the only method that does not require patients to produce sperm and egg cells. The same arguments that were used against in vitro conception in the past are now being used against cloning. It is years later and in vitro cloning is generally applied and accepted by society. I am of the opinion that the same will happen with regard to human cloning.

There is an argument that cloning must be prohibited because it is unsafe. Distorted ideas in this regard were proven wrong. Are these distorted ideas justified to question the safety of cloning and the cloning process you may ask. The answer, according to me, is a definite no. Human cloning does have many advantages. That includes assistance with infertility, prevention of Down Syndrome and recovery from leukemia.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept